
PAM
Mesenchyma
Proneural
Proliferative
Unclassified
Signature
Mesenchyma
Proneural
Proliferative
3
2
1
0
−1
−2
−3

Figure 1

Figure 2



PAM Proneural (PN) subtype
PLACEBO (48)
BEVACIZUMAB (39)
1.0
0.8
0.6
0.4
0.2
0.0
12.2
17.1
0
10
20
30
40
OS (months)
39 32 14 6 1
48 32 11 4 0

Figure 3



Non−Proneural
Proneural
NCAM1
OMG
PRKCZ
GALNT13
GPR17
DNM3
FERMT1
SNAP91
ABHD6
PFN2
KIAA1244
ATP6V1G2
ERBB3
KLRC3
DLL1
BCAS1
SOX8
TMEFF2
SERPINH1
GRIA2
AKT3
LGALS3
TIMP1
DPP10
ERBB4
DLL3
CSDC2
BEX1
POSTN
S100A4
ZBTB18
EPHB1
OLIG2
CSMD3
MAP2
ASCL1
CTNND2
NDRG4
EMP3
SUSD5
PTX3
CNTN3
LIF
BCL3
PRF1
SYT4
GABBR1
PHLPP1
EFNB2
KCND2
FBLIM1
FAM26C
COL6A3
LUM
CHI3L1
C8orf4
SERPINE1
SCG3
TXNDC5
PTPRO
MXD4
PROM1
NDRG2
DDX25
BCAN

Figure 4



Proneural subtype predicted by shrunkedn centroid classification (PAMR)
PLACEBO (49)
BEVACIZUMAB
1.0
0.8
0.6
0.4
0.2
0.0
0
10
20
30
40
OS (months)
15.1
12.0
37
49
31
31
12
9
6
3
1
0

Figure 5




Distribution of the continuous Proneural score across subtypes
Proneural score
2.0
1.5
1.0
0.5
0.0
−0.5
−1.0
Mesenchymal
Proliferative
Proneural
Unclassified
PAM subtype

Figure 6


A
High continuous Proneural score
PLACEBO (86)
BEVACIZUMAB (83)
1.0
0.8
0.6
0.4
0.2
0.0
13.0
15.7
0
10
20
30
40
OS (months)
83 66 33 12 1
86 57 21 5 0
B
Low continuous Proneural score
PLACEBO (87)
BEVACIZUMAB (83)
17.2
17.5
83 70 36 7 1
87 67 39 10 0